Tuesday Poster Session Category: Biliary/Pancreas P4425 - Hyperkinetic Biliary Dyskinesia Following Discontinuation of GLP-1 Receptor Agonist Therapy Tuesday, October 28, 2025 10:30 AM - 4:00 PM PDT Location: Exhibit Hall Presenting Author(s) McKenna Andrews, MD 1 , David W
Optimized placement isnt optional
Improves insulin sensitivity Higher levels of glutathione may help lower the risk of diabetes
You dont need to be obese to start a GLP-1. In practice, though, you doat least according to the US Food and Drug Administration, which has only approved GLP-1 drugs for people with clinical obesity or Type 2 diabetes and for people who are overweight with weight-related comorbidities
This means you eat less, experience fewer cravings, and are more likely to stick with a healthy lifestyle